Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib in First-line EGFR+ T790M+ NSCLC
NCT02841579Phase 2Completed
- Sponsor
- MEDSIR
- Start
- Sep 2016
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by MEDSIR. Primary endpoint: Objective Response Rate at 28 months. Started Sep 2016; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02841579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02841579.